CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 820606654
- Phone
- (650) 331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 94 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-19 | Spigelman Melvin K Director | Returned to the company · Stock Option (right to buy) | −23,742 | 0 | ||
| 2026-03-19 | Readnour Robin Shane Director | Grant or award · Stock Option (right to buy) | +20,724 | 20,724 | ||
| 2026-03-19 | Readnour Robin Shane Director | Returned to the company · Stock Option (right to buy) | −20,724 | 0 | ||
| 2026-03-19 | Readnour Robin Shane Director | Grant or award · Stock Option (right to buy) | +23,742 | 23,742 | ||
| 2026-03-19 | Readnour Robin Shane Director | Returned to the company · Stock Option (right to buy) | −23,742 | 0 | ||
| 2026-03-19 | Easom Eric Chief Executive Officer | Grant or award · Stock Option (right to buy) | +249,999 | 249,999 | ||
| 2026-03-19 | Easom Eric Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −249,999 | 0 | ||
| 2026-03-19 | Easom Eric Chief Executive Officer | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2026-03-19 | Easom Eric Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −225,000 | 0 | ||
| 2026-03-19 | Easom Eric Chief Executive Officer | Grant or award · Stock Option (right to buy) | +267,650 | 267,650 | ||
| 2026-03-19 | Easom Eric Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −267,650 | 0 | ||
| 2026-03-03 | Williams Sarah Joanne Principal Accounting Officer | Sale | −327 | $1.06 | $347 | 66,848 |
| 2026-02-20 | Eizen Joshua M See Remarks | Grant or award | +50,000 | 207,499 | ||
| 2026-02-20 | Eizen Joshua M See Remarks | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2026-02-20 | Day Lucy Chief Financial Officer | Grant or award | +38,000 | 118,363 | ||
| 2026-02-20 | Day Lucy Chief Financial Officer | Grant or award · Stock Option (right to buy) | −77,000 | 77,000 | ||
| 2026-02-20 | Williams Sarah Joanne Principal Accounting Officer | Grant or award | +48,375 | 67,175 | ||
| 2026-02-20 | Easom Eric Chief Executive Officer | Grant or award | +112,250 | 368,630 | ||
| 2026-02-20 | Easom Eric Chief Executive Officer | Grant or award · Stock Option (right to buy) | +224,500 | 224,500 | ||
| 2026-02-20 | Chanda Sanjay Chief Development Officer | Grant or award | +38,000 | 118,823 |
Page 5 of 10 · 191 trades